JP2008538355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538355A5 JP2008538355A5 JP2008505659A JP2008505659A JP2008538355A5 JP 2008538355 A5 JP2008538355 A5 JP 2008538355A5 JP 2008505659 A JP2008505659 A JP 2008505659A JP 2008505659 A JP2008505659 A JP 2008505659A JP 2008538355 A5 JP2008538355 A5 JP 2008538355A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- expression
- antisense oligonucleotide
- acc2
- acc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66953005P | 2005-04-08 | 2005-04-08 | |
| PCT/US2006/013536 WO2006110775A2 (en) | 2005-04-08 | 2006-04-10 | Compositions and their uses directed to aceytl-coa carboxylases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538355A JP2008538355A (ja) | 2008-10-23 |
| JP2008538355A5 true JP2008538355A5 (enExample) | 2009-04-16 |
Family
ID=37087656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505659A Withdrawn JP2008538355A (ja) | 2005-04-08 | 2006-04-10 | アセチル−ＣｏＡカルボキシラーゼに関する組成物およびそれらの用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8299041B2 (enExample) |
| EP (1) | EP1871351A4 (enExample) |
| JP (1) | JP2008538355A (enExample) |
| AU (1) | AU2006235451A1 (enExample) |
| CA (1) | CA2603206A1 (enExample) |
| WO (1) | WO2006110775A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9133509B2 (en) | 2012-03-22 | 2015-09-15 | Lgc Genomics Limited | Polymerase chain reaction detection system |
| HK1217448A1 (zh) | 2013-09-12 | 2017-01-13 | 辉瑞大药厂 | 乙酰辅酶a羧化酶抑制剂用於治疗寻常痤疮的用途 |
| KR102304280B1 (ko) * | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
| TW202221120A (zh) * | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | 用於治療代謝症候群之組成物及方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992002258A1 (en) * | 1990-07-27 | 1992-02-20 | Isis Pharmaceuticals, Inc. | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US7572582B2 (en) * | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| WO2002040637A2 (en) * | 2000-11-20 | 2002-05-23 | Isis Pharmaceuticals, Inc. | Antisense modulation of pi3k p85 expression |
| US20050124568A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA) |
| US20030158403A1 (en) * | 2001-07-03 | 2003-08-21 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| AU2003291755A1 (en) * | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| WO2004063715A2 (en) * | 2003-01-10 | 2004-07-29 | The Trustees Of Columbia University In The City Of New York | Methods of using crystal structure of carboxyltransferase domain of acetyl-coa carboxylase, modulators thereof, and computer methods |
| WO2004087752A2 (en) | 2003-04-04 | 2004-10-14 | Ingenium Pharmaceuticals Ag | Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders |
| WO2004108081A2 (en) * | 2003-06-02 | 2004-12-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide synthesis with alternative solvents |
| WO2005007859A2 (en) * | 2003-07-11 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US7150969B2 (en) * | 2004-06-04 | 2006-12-19 | Rosetta Inpharmatics Llc | Alternatively spliced isoform of acetyl-CoA carboxylase 2 (ACC2) |
-
2006
- 2006-04-10 JP JP2008505659A patent/JP2008538355A/ja not_active Withdrawn
- 2006-04-10 CA CA002603206A patent/CA2603206A1/en not_active Abandoned
- 2006-04-10 WO PCT/US2006/013536 patent/WO2006110775A2/en not_active Ceased
- 2006-04-10 AU AU2006235451A patent/AU2006235451A1/en not_active Abandoned
- 2006-04-10 US US11/910,606 patent/US8299041B2/en not_active Expired - Fee Related
- 2006-04-10 EP EP06749800A patent/EP1871351A4/en not_active Withdrawn
-
2012
- 2012-09-14 US US13/619,362 patent/US20130109849A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012050438A5 (enExample) | ||
| JP2012050439A5 (enExample) | ||
| JP2009508527A5 (enExample) | ||
| JP2009506124A5 (enExample) | ||
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| JP7662216B2 (ja) | 複合体及びその調製方法と使用 | |
| JP2010539950A5 (enExample) | ||
| Wen et al. | Opportunities and challenges of algal fucoidan for diabetes management | |
| Van Rooij et al. | MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles | |
| JP2016530882A5 (enExample) | ||
| JP2012527444A5 (enExample) | ||
| EP3472362B1 (en) | Papd5 and papd7 inhibitors for treating an hepatitis b infection | |
| JP2017509354A5 (enExample) | ||
| JP2011504362A5 (enExample) | ||
| JP2010500290A5 (enExample) | ||
| Saneyoshi et al. | A general method for the synthesis of 2 ‘-O-cyanoethylated oligoribonucleotides having promising hybridization affinity for DNA and RNA and enhanced nuclease resistance | |
| JP2005520489A5 (enExample) | ||
| JP2003523739A5 (enExample) | ||
| JP2009524419A5 (enExample) | ||
| Sharma et al. | Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? | |
| JP2020533334A5 (enExample) | ||
| WO2001025248A2 (en) | Design of high affinity rnase h recruiting oligonucleotide | |
| JP2010512747A5 (enExample) | ||
| JP2012029693A5 (enExample) | ||
| JP7095893B2 (ja) | アンチセンスオリゴ核酸 |